Renoprotective effects of dulaglutide in patients with T2DM and CKD

被引：0
|
作者：
Charlotte M. Sorensen
Jens J. Holst
机构：
[1] University of Copenhagen,Department of Biomedical Sciences
来源：
Nature Reviews Nephrology | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.
引用
收藏
页码：659 / 660
页数：1
相关论文
共 50 条
12345